



Upon successful completion of this free training and the associated case assessment, eligible participants may apply to the relevant state departments of health for authority to prescribe Section 100 (\$100) drugs for the management of hepatitis B in Australia.

Target Audience: General Practitioners, Nurse Practitioners, other community based medical practitioners based in Australia.

## **Dates and Times:**

Part 1: Wednesday, 13 November, 6:30-8:30PM (AEDT) Part 2: Wednesday, 20 November, 6:30-8:30PM (AEDT) Part 3: Wednesday, 27 November, 6:30-8:30PM (AEDT)

Virtual Attendance: Online - Microsoft Teams

## **Speakers**

- Dr Nada Andric, experienced HBV s100 prescriber, The Haymarket Foundation
- Dr Scott Davison, Gastroenterologist, Liverpool Hospital

## **Course Components**

This course will be presented as a mix of self-paced and live facilitated learning, providing attendees with an opportunity to discuss and practice strategies with peers and specialists. This is comprised of:

- Online Learning Modules (OLM)
- Three 2-hour interactive webinars via Teams, accessed through the ASHM OLM
- Case Studies
- Multiple choice quiz
- Presentations and case discusses will be delivered by specialists and primary care providers with expertise in hepatitis b

Total expected time to complete all self-paced and live components = 11 hours



## For further details or assistance contact:

ASHM Education 04310 320 429 education@ashm.org.au

This activity is funded by SWSPHN.

This course is free to attend for professions aligned with the target audience who practice in NSW>

ASHM is an RACGP-accredited CPD provider under the RACGP CPD Program. This is an RACGP-approved CPD activity under the RACGP CPD Program. This activity has been approved for the following hours and types:

Educational Activities (EA): 6.0 hours

Reviewing Performance (RP): 3.5 hours

This course and associated activities are accredited with ACRRM for 6 educational activity PDP units, 4 additional CPD requirements and 5 performance review PDP units in 2023-2025 triennium.